Current updates in management of Clostridium difficile infection in cancer patients.

Muhammad Aziz, Rawish Fatima, Lindsey N Douglass, Omar Abughanimeh, Shahzad Raza

Journal: Current medical research and opinion 2020;35(3):473-478

PMID: 29888965

Abstract

BACKGROUND

Clostridium difficile infection (CDI) is a significant health burden, now recognized as the leading cause of acquired diarrhea in patients receiving antibiotic therapy. Complications of infection with this pathogen include severe diarrhea, causing electrolyte imbalances, dehydration, hemodynamic instability, toxic megacolon, shock, and death. Hence it is extremely paramount to stay updated on management options for this infection, especially in cancer patients.

REVIEW

This article presents an in-depth review of literature on the treatment modalities available for CDI in cancer patients. Relevant articles highlighting therapeutic and symptomatic management of CDI patients with underlying malignancy have been summarized.

CONCLUSIONS

Despite the current options available, more studies are needed to assess the newer therapeutic options that are being employed for populations other than cancer patients.

Address: a Department of Internal Medicine , University of Kansas Medical Center , Kansas City , MO , USA.; b Department of Medicine , Dow University of Health Sciences , Karachi , Pakistan.; c Pharmacy Department , Saint Luke's Hospital of Kansas City , Kansas City , MO , USA.; d Department of Internal Medicine , Saint Luke's Hospital of Kansas City/University of Missouri , Kansas City , MO , USA.; e Department of Hematology & Oncology , St. Luke's Hospital of Kansas City/University of Missouri , Kansas City , MO , USA.

Link outs

Free resources

Other Literature Sources:

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.